Clarity

Klarna unveils conscious badges powered by Clarity AI, the world's first assessment of electronics brands' environmental achievements

Retrieved on: 
Thursday, March 16, 2023
Electronics, Dec, Partnership, Life, Carbon, Nudie Jeans, Global warming potential, Climate, Clarity, Sustainability, System, Online shopping, Retail, Coal, Klarna

"We're thrilled to deepen our partnership with Klarna to develop conscious badges, the first-ever assessment of electronics brands' achievements providing transparency at scale for consumers around the world.

Key Points: 
  • "We're thrilled to deepen our partnership with Klarna to develop conscious badges, the first-ever assessment of electronics brands' achievements providing transparency at scale for consumers around the world.
  • Conscious badges are currently accessible to consumers after they make an electronics purchase via the transactions details page of the Klarna App.
  • In January this year, Klarna launched a resell feature enabling shoppers in Sweden to resell their previous purchases directly through the Klarna App.
  • Conscious badges are available now to Klarna App users worldwide.

Klarna unveils conscious badges powered by Clarity AI, the world's first assessment of electronics brands' environmental achievements

Retrieved on: 
Thursday, March 16, 2023
Electronics, Dec, Partnership, Life, Carbon, Nudie Jeans, Global warming potential, Climate, Clarity, Sustainability, System, Online shopping, Retail, Coal, Klarna

"We're thrilled to deepen our partnership with Klarna to develop conscious badges, the first-ever assessment of electronics brands' achievements providing transparency at scale for consumers around the world.

Key Points: 
  • "We're thrilled to deepen our partnership with Klarna to develop conscious badges, the first-ever assessment of electronics brands' achievements providing transparency at scale for consumers around the world.
  • Conscious badges are currently accessible to consumers after they make an electronics purchase via the transactions details page of the Klarna App.
  • In January this year, Klarna launched a resell feature enabling shoppers in Sweden to resell their previous purchases directly through the Klarna App.
  • Conscious badges are available now to Klarna App users worldwide.

U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease

Retrieved on: 
Tuesday, March 14, 2023
The New England Journal of Medicine, Tradition, Brain, Veteran, Pathology, Co-promotion, Priority review, VHA, Lecanemab, Patient, Clarity, FDA, Clinical trial, PDUFA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, AD, Plaque, Immunoglobulin G, Pharmaceutical industry, Alzheimer's disease, Biogen, Disease, Eisai

The VHA's careful consideration and timely action to make LEQEMBI available approximately two months after the FDA approved LEQEMBI under the accelerated approval pathway shows its continued commitment to veterans living with AD.

Key Points: 
  • The VHA's careful consideration and timely action to make LEQEMBI available approximately two months after the FDA approved LEQEMBI under the accelerated approval pathway shows its continued commitment to veterans living with AD.
  • If approved under the traditional pathway, the FDA will update the label for LEQEMBI, which will include new data that has been evaluated by the FDA.
  • The FDA has determined that the results of Clarity AD will serve as the confirmatory study to verify the clinical benefit of LEQEMBI.
  • On the same day that LEQEMBI received its Accelerated approval, Eisai submitted the supplemental Biologics License Application (sBLA) to the FDA for approval under the Traditional pathway.

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Retrieved on: 
Monday, March 6, 2023
The New England Journal of Medicine, Brain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Co-promotion, Pathology, Priority review, BIIB, Lecanemab, Patient, Clarity, FDA, Clinical trial, Oncology Drug Advisory Committee, PDUFA, Prescription Drug User Fee Act, Food, Advisory Committee, AD, Plaque, Immunoglobulin G, Pharmaceutical industry, Medical imaging, Alzheimer's disease, Biogen, Eisai

The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023.

Key Points: 
  • The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023.
  • The FDA is currently planning to hold an Advisory Committee to discuss this application but has not yet publicly announced the date of the meeting.
  • On the same day that LEQEMBI received its accelerated approval, Eisai submitted the sBLA to the FDA for approval under the traditional pathway.
  • The sBLA is based on the findings from Eisai's recently published large, global confirmatory Phase 3 clinical trial, Clarity AD.

Clarity AI and CDP announce environmental data product partnership

Retrieved on: 
Tuesday, March 7, 2023
Professional Services, Data Management, Technology, Other Technology, Finance, Software, Partnership, ESG, Organization, ETF, Distribution, CDP, Asset management, Clarity

Clarity AI’s extensive global client network manages tens of trillions of assets and counts on the Clarity AI platform to turn raw data into products that are easily consumable, including scores and analytics for integration in third-party platforms.

Key Points: 
  • Clarity AI’s extensive global client network manages tens of trillions of assets and counts on the Clarity AI platform to turn raw data into products that are easily consumable, including scores and analytics for integration in third-party platforms.
  • Through this partnership, CDP data will be used in Clarity AI's Net Zero tool, which supports financial institutions in managing and reporting their Net Zero alignment, in line with the industry-backed Net Zero Investment Framework (NZIF).
  • CDP’s fund rating Climetrics – a free-to-search database of global ETFs and funds rated on their environmental performance, will also be calculated by Clarity AI.
  • Laurent Babikian, Global Director Data Products and Distribution CDP said, “As CDP holds the world’s largest self-reported environmental dataset, this partnership will ensure Clarity AI clients have access to the most comparable, science-based and comprehensive environmental data available.

Clarity AI Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023

Retrieved on: 
Thursday, March 2, 2023
Software, Mobile, Wireless, Professional Services, Philanthropy, Data Management, Sustainability, Technology, Small Business, Artificial Intelligence, Environment, Finance, Other Technology, Other Philanthropy, Organization, Editorial, MrBeast, Early stage innovation company, ITunes, AI, NASA, Clarity, Sales

Clarity AI has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.

Key Points: 
  • Clarity AI has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
  • “We are constantly innovating to help investors, companies and consumers create a more sustainable world,” said Rebeca Minguela, Founder & CEO of Clarity AI.
  • The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year.
  • Fast Company’s Most Innovative Companies issue (March/April 2023) is available online here , as well as in-app form via iTunes, and on newsstands beginning March 14.

C2P Enterprises Launches 'A Woman's Clarity' Program, Invites Advisors to Special International Women's Day Event

Retrieved on: 
Thursday, March 2, 2023
MATCH International Women's Fund, Insurance, Woman, EST, International Women's Day, Retirement, Female, Peter Schlumbohm, Male, Hammer, C2P, Q&A, Podcast, CFS, Clarity

CLEVELAND, March 2, 2023 /PRNewswire/ -- C2P Enterprises, a holding company comprised of four distinct brands, each designed to simplify financial planning for advisors and their clients, announces the launch of their latest innovative program for financial advisors, A Woman's Clarity. Dedicated to helping financial professionals increase their footprint and successfully engage with more female advisors, clients, and prospects, program participants will gain knowledge through ongoing thought leadership and networking, including a newly launched podcast series, live events, blogs, and more. To subscribe to the A Woman's Clarity podcast, click here.

Key Points: 
  • New program helps financial professionals engage female advisors, clients, and prospects through ongoing thought leadership and networking and a newly launched podcast series.
  • CLEVELAND, March 2, 2023 /PRNewswire/ -- C2P Enterprises , a holding company comprised of four distinct brands, each designed to simplify financial planning for advisors and their clients, announces the launch of their latest innovative program for financial advisors, A Woman's Clarity.
  • To coincide with the program launch, the first special event for A Woman's Clarity will be held on International Women's Day, Wednesday, March 8, at 11:00 a.m. EST.
  • The 45-minute session will feature an open discussion format with free-flowing dialogue among panelists and Q&A from the audience.

Diligent Adds PwC Canada, Vervantis, Clarity AI and Others to Its Growing List of Partners, Extending Ability To Integrate With the Industry’s Leading GRC Platform

Retrieved on: 
Tuesday, February 28, 2023
Professional Services, Security, Technology, Software, Consulting, Artificial Intelligence, Nation Group, Software as a service, Audit, ESG, BIG, Organization, Partnership, Risk, Proxy Governance, Inc., PwC, GRC, Canada, Design Worldwide Partnership, SVP, Clarity, Media Group, CYLK, Consultant, Risk management, Accounting, Diligence

“We’re thrilled to welcome great partners across the consultancy, sustainability, IT and legal spaces,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent.

Key Points: 
  • “We’re thrilled to welcome great partners across the consultancy, sustainability, IT and legal spaces,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent.
  • Organizations can now leverage Diligent’s entire robust GRC solutions suite and Brave Consultancy's leading advisory services to make better decisions, faster.
  • Clarity AI – Clarity AI is a leading sustainability technology platform.
  • Through PwC Canada’s partnership with Diligent, customers can now leverage Diligent’s leading GRC solutions to mitigate and get ahead of risk to build resiliency.

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Retrieved on: 
Tuesday, February 28, 2023
Amyloid beta, Ministry of Health, Labour and Welfare, Lecanemab, Alzheimer's disease, Ministry, Priority review, Ministry of Health (Saudi Arabia), Disease, Biologics license application, European Medicines Agency, BLA, Brain, Research, The New England Journal of Medicine, FDA, Neurotoxicity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National Medical Products Administration, Co-promotion, Medicines and Healthcare products Regulatory Agency, EMA, MAA, PMDA, AD, Pharmaceuticals and Medical Devices Agency, Clarity, Medication, MCI, Food, NMPA, Phase, MHLW, Procedure, Pharmaceutical industry, Medical device, Health, Eisai, Biogen

TOKYO, Feb 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China.

Key Points: 
  • TOKYO, Feb 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China.
  • In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022.
  • In the U.S., lecanemab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on January 6, 2023.
  • On the same day, Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway.

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Retrieved on: 
Monday, February 27, 2023
Ministry of Health, Labour and Welfare, Lecanemab, Ministry, BIIB, Corporation, Priority review, Ministry of Health (Saudi Arabia), Disease, Biologics license application, European Medicines Agency, BLA, The New England Journal of Medicine, Brain, Research, FDA, Neurotoxicity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Headquarters, National Medical Products Administration, Co-promotion, Medicines and Healthcare products Regulatory Agency, EMA, MAA, PMDA, AD, Pharmaceuticals and Medical Devices Agency, Clarity, Medication, MCI, Food, NMPA, Phase, MHLW, Procedure, Pharmaceutical industry, Medical device, Health, Eisai, Biogen

In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022.

Key Points: 
  • In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022.
  • Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
  • In the U.S., lecanemab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on January 6, 2023.
  • On the same day, Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway.